Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease. The company was formed in 1996 to commercialise research from Northwestern University showing that soluble oligomers — rather than insoluble plaque — are the early and persistent trigger of synaptic dysfunction in Alzheimer's. Its lead candidate, sabirnetug (ACU193), is a humanised monoclonal antibody that selectively binds AβOs; a subcutaneous formulation is being developed with Halozyme's ENHANZE technology, and Acumen is collaborating with JCR Pharmaceuticals on an Enhanced Brain Delivery (EBD) programme using transferrin-receptor-targeted blood-brain-barrier transport. In October 2026 the company reported that the Phase 2 ALTITUDE-AD trial of intravenous sabirnetug missed its primary endpoint and discontinued development of the asset, moving to cash-conservation measures and an evaluation of strategic alternatives.
Board approved 90% workforce reduction (52 positions) and initiated strategic-alternatives evaluation (SEC Form 8-K Item 2.05)
In an SEC Form 8-K Item 2.05 filing on November 5, 2026, clinical-stage Alzheimer's biopharma Acumen Pharmaceuticals disclosed that its board approved a deep corporate restructuring cutting 52 full-time employees (~90% of its workforce) initiated on November 2, 2026. The restructuring follows the discontinuation of lead monoclonal antibody sabirnetug after failing its Phase 2 ALTITUDE-AD trial, with Acumen prepaying its $30 million loan facility with K2 HealthVentures and incurring $7.75 million in cash severance charges while evaluating strategic alternatives.
Acumen Pharmaceuticals filed an SEC Form 8-K Item 2.05 disclosing a 90% workforce reduction (52 full-time roles), prepaying its $30M K2 HealthVentures debt facility and halting its Phase 2 ALTITUDE-AD Alzheimer's trial to conserve cash while exploring strategic alternatives.